Select Page

A curated selection of EPHA’s mentions in worldwide media outlets.

2017

ACCESS TO MEDICINE IS NOW A MATTER SOCIAL JUSTICE AND COHESION

HEALTH DAILY

21 December 2017

Interview with Yannis Natsis, Policy Manager for Universal Access & Affordable Medicines, European Public Health Alliance (EPHA) (Greek language)


NEW REPORT: MOST INFANT FORMULA CLAIMS NOT BASED ON SCIENCE; MOSTLY MARKETING RESEARCH

HUFFPOST

14 December 2017

The investigative report by The Changing Markets Foundation, Globalization Monitor, SumOfUs and the European Public Health Alliance (EPHA) calls for a comprehensive overhaul of infant formula products and their regulation so that only claims based on unequivocal scientific advice are used.


SMOKE AND MIRRORS OR CLEAR COMMUNICATION? INDUSTRY CLASHES OVER EVOLVED NUTRITION LABENEW REPORT: MOST INFANT FORMULA CLAIMS NOT BASED ON SCIENCE; MOSTLY MARKETING RESEARCH

FOOD NAVIGATOR

1 December 2017

The European Consumer Organisation (BEUC), the European Heart Network (EHN) and the European Public Health Alliance (EPHA) issued a joint statement ​yesterday both praising and condemning the ENL. […] “Such labelling must be understood at a glance by consumers and allow straightforward comparison between products,” they wrote.


AIR POLLUTION, EUROPE’S LARGEST ENVIRONMENTAL HEALTH HAZARD

EU OBSERVER

3 May 2017

“Financial incentives are vital to ensure the proper implementation of EU law. Member states should not regard implementing policies as costs but rather as an investment,” EPHA policy coordinator Zoltan Massay-Kosubek told EUobserver.


FDA APPROVES SOVALDI AND HARVONI FOR PEDRIATIC HEPATITIS C PATIENTS

HEPATITIS NEWS TODAY

10 April 2017  

In other related news, the European Public Health Alliance (EPHA) plus 30 other civil society organizations from 17 European countries recently filed a coordinated patent opposition on Sovaldi and Harvoni contesting the high prices of the drugs. Results of this initiative might translate into more accessible treatments for European patients.


TREINTA ORGANIZACIONES SE UNEN PARA REVOCAR EL MONOPOLIO DEL FÀRMACO DE LA HEPATITIS C

ELDIARIO.ES

04 April 2017  

Un grupo de más de 30 organizaciones –entre las que están Médicos Sin Fronteras (MSF), Médicos del Mundo, Salud por Derecho o la Alianza Europea para la Salud Pública– se han unido para intentar que la Oficina Europea de Patentes revoque la licencia que permite a la empresa farmacéutica Gilead mantener el monopolio sobre el medicamento para la hepatitis C, sofosbuvir, cuyo tratamiento tiene un precio que ronda los 25.000 euros en España.


MÉDICINS DU MONDE S’OPPOSE À UN AUTRE BREVET SUR LE SOFOSBUVIR : 30 ONG ET ASSOCIATIONS DANS 17 PAYS NOUS REJOIGNENT

MÉDICINES DU MONDE

27 March 2017  

Notre précédente action a ouvert la voie : aujourd’hui, 30 ONG dans 17 pays se mobilisent. Dix sections du réseau international de Médecins du Monde en Europe,13 sections de Médecins Sans Frontières en Europe et 5 associations nationales et l’Alliance européenne pour la santé publique rejoignent cette seconde opposition au brevet.


UNA TREINTENA DE ORGANIZACIONES DESAFÍAN LA PATENTE DEL MEDICAMENTO CONTRA LA HEPATITIS C

ACTUALIDAD HUMANITARIA

29 March 2017  

A día de hoy, 30 organizaciones no gubernamentales y de la sociedad civil de 17 países europeos están comprometidas en este nuevo procedimiento. 10 delegaciones de la red internacional de Médicos del Mundo y 13 de la red de Médicos sin Fronteras en Europa, 5 organizaciones sociales nacionales y la Alianza Europea para la Salud Pública se unen a esta nueva oposición. En España, Médicos del Mundo y Salud por Derecho son las dos entidades que se oponen a la patente.


SOFOSBUVIR: MÉDICOS DEL MUNDO RECURRE LA PATENTE EN LA UNIÓN EUROPEA

PERIODISTAS EN ESPAÑOL.COM

29 March 2017  

Nuestro procedimiento anterior ha allanado el camino. A día de hoy, 30 organizaciones no gubernamentales y de la sociedad civil de 17 países europeos están comprometidas en este nuevo procedimiento. 10 delegaciones de la red internacional de Médicos del Mundo y 13 de la red de Médicos sin Fronteras en Europa, 5 organizaciones sociales nacionales y la Alianza Europea para la Salud Pública se unen a esta nueva oposición. En España, Médicos del Mundo y Salud por Derecho son las dos entidades que se oponen a la patente.


EUROPEAN PUBLIC HEALTH ALLIANCE JOINS PATENT OPPOSITION FOR HCV TREATMENT

HEPATITIS NEWS TODAY

28 March 2017  

The European Public Health Alliance (EPHA) is one of 30 civil society organizations from 17 European countries to file a coordinated patent opposition on sofosbuvir with the European Patent Office (EPO). Sofosbuvir is a hepatitis C therapy sold under the brand name Sovaldi among others.


PIDEN FIN AL MONOPOLIO SOBRE UN MEDICAMENTO CLAVE PARA LA HEPATITIS C

PMFARMA

28 March 2017  

30 organizaciones no gubernamentales y de la sociedad civil de 17 países europeos han presentado una oposición a la patente de Sovaldi (sofosbuvir) ante la Oficina Europea de Patentes (EPO). Entre ellas, 10 delegaciones de la red internacional de Médicos del Mundo, 13 de la red de Médicos sin Fronteras en Europa, cinco organizaciones sociales nacionales (entre ellas la española Salud por Derecho) y la Alianza Europea para la Salud Pública (EPHA).


MÉDICINS DU MONDE S’OPPOSE À UN AUTRE BREVET SUR LE SOFOSBUVIR : 30 ONG ET ASSOCIATIONS DANS 17 PAYS NOUS REJOIGNENT

MÉDICINES DU MONDE

27 March 2017  

Notre précédente action a ouvert la voie : aujourd’hui, 30 ONG dans 17 pays se mobilisent. Dix sections du réseau international de Médecins du Monde en Europe,13 sections de Médecins Sans Frontières en Europe et 5 associations nationales et l’Alliance européenne pour la santé publique rejoignent cette seconde opposition au brevet.


AIDES DÉPOSE UNE OPPOSITION AU BREVET DU SOVALDI

SERONET

27 March 2017  

Ce même jour, onze sections de Médecins du Monde et treize de Médecins sans Frontières déposent également une opposition sur ce brevet ainsi que des organisations non gouvernementales européennes mobilisées pour l’accès aux traitements (2).
(2) : European public health alliance (EPHA), Just treatment (Grande-Bretagne), Salud por Derecho (Espagne), Praksis (Greece), Access to medicines (Ireland).


HÉPATITE C : NOUVELLE OFFENSIVE CONTRE LE BREVET C

LIBÉRATION

27 March 2017  

A l’initiative de Médecins du Monde, une opposition au brevet sur le Sofosbuvir a été déposée devant l’Office européen des brevets (OEB), portant sur le composant de base qui permet de fabriquer le médicament. L’action est soutenue par trente ONG, dont treize sections de Médecins sans frontières en Europe ainsi que l’Alliance européenne pour la santé publique. 


PRAKSIS IS INVOLVED IN THE EUROPEAN PATENT APPLICATION AGAINST THE HEPATITIS C GRUG PATENT

YGEIA

27 March 2017  

11 offices of Doctors of the World (Belgium, France, Germany, Greece, Luxembourg, Netherlands, Portugal, Spain, Sweden, Switzerland, UK), 13 Médecins Sans Frontières (Italy, Greece, France, Netherlands, Germany, Austria , Luxembourg, Sweden, Norway, Denmark, Czech Republic, the UK, Ireland) and 6 other organizations active in European countries ( European Public Health Alliance EPHA ], Just Treatment , Salud por Derecho, AIDES [France], PRAKSIS [Greece], Access to Medicines [Ireland]) are joining their voice in yet another dynamic initiative to access affordable medicines for citizens living in Europe.


LA PATENTE DE SAVOLDI, CUESTIONADA POR UNA TREINTENA DE ORGANIZACIONES

DIARIO FARMA

27 March 2017  

A día de hoy, 30 organizaciones no gubernamentales y de la sociedad civil de 17 países europeos han presentado una oposición a la patente de Sovaldi (sofosbuvir) ante la Oficina Europea de Patentes (EPO). Entre ellas, 10 delegaciones de la red internacional de Médicos del Mundo, 13 de la red de Médicos sin Fronteras en Europa, cinco organizaciones sociales nacionales (entre ellas la española Salud por Derecho) y la Alianza Europea para la Salud Pública (EPHA).


EUROPEAN COMMISSION PUBLISHES LONG-AWAITED STUDY ON OFF-LABEL USE: INDUSTRY REACTS

LEXOLOGY

07 March 2017  

The study, which was commissioned to the Dutch National Institute for Public Health and the Environment (Nivel) and the European Public Health Alliance (EPHA), was intended to gather information in order to identify the need for coordination of off-label use of medicines at the EU level, focusing on the one hand on – scientific – public health aspects, and on the other hand on the – legal – regulatory framework for the off-label use of medicines.


DE LA HTA A LA EMA: LOS ASUNTOS QUE VAN A MARCAR LA POLÍTICA FARMACÉUTICA DURANTE 2017

EL GLOBAL.NET

03 February 2017  

La Alianza Europea por la Salud Pública (EPHA, por sus siglas en inglés), a través de su responsable para Acceso Universal y Medicamentos Asequibles, Yannis Natsis, ha señalado cuáles son los cinco asuntos más candentes que marcarán la política farmacéutica comunitaria hasta el 31 de diciembre.


THE REAL DIVIDES ON EUROPEAN HTA

APPLIED CLINICAL TRIALS

30 January 2017  

The European Public Health Alliance says giving competence to EMA for HTA would be “counter-productive”, creating an “excessive and unchallenged concentration of power.” 


LA INDUSTRIA Y LA SOCIEDAD CONECTAN EN SU VISIÓN SOBRE EL FUTURO DE LA HTA EN EUROPA 

EL GLOBAL.NET

27 January 2017  

“Las evaluaciones de las tecnologías sanitarias a menudo tienen un impacto directo sobre las decisiones de precios y reembolsos”, señala la EPHA. 


SOME MORE EQUAL THAN OTHERS

APPLIED CLINICAL TRIALS

24 January 2017  

The concern about medicine prices as a component of the challenges is reflected in many contributions to the debate. Just at the end of January, the European Public Health Alliance spoke of “the access & innovation crises Europe faces primarily due to the exorbitant prices of medicines,” and told drug manufacturers that “they need to invest in real innovation and not towards a proliferation of me-too medicines.”


‘MONEY HAS TRUMPED THE ENVIRONMENT’ OVER EU-CANADA DEAL – CAMPAIGNERS

SPUTNIKNEWS.COM

13 January 2017  

​”The Committee has decided not to follow the progressive line marked by the Employment and Social Affairs (EMPL) Committee and to address citizens’ concerns. Obtaining a better deal for health and consumers is still possible, but the opportunities are beginning to thin out,” said Zoltán Massay-Kosubek, EPHA Policy Coordinator for Healthy Trade.


TRANSFORMING HEALTH CARE THROUGH DISRUPTIVE INNOVATION: WILL YOUR DATA CURE YOU?

POLITICO

12 January 2017  

POLITICO recently gathered a group of Commission officials, researchers, health care professionals and industry representatives to ponder how Europe should approach the use of technology to improve health care.


GRECIA, INCHIESTA SU MAXIBUCO CREATO DA NOVARTIS. SPUNTA NOME GOVERNATORE BANCA CENTRALE

MONDOGRECO.NET

09 January 2017  

Intanto Yannis Natsis, Policy Coordinator presso la European Public Health Alliance, ha dichiarato non solo che le accuse di corruzione dimostrano che l’industria farmaceutica ancora una volta abusa del suo strapotere ma che, nonostante la Grecia potrebbe essere descritta come un paese in bancarotta, numerosi medicinali con prezzi esorbitanti, soprattutto quelli oncologici, sono ancora pienamente rimborsati dallo Stato: con profitti fiume per le multinazionali.


GRECIA, INCHIESTA SU MAXIBUCO CREATO DA NOVARTIS. SPUNTA NOME GOVERNATORE BANCA CENTRALE

IL FATTO QUOTIDIANO

8 January 2017 

Intanto Yannis Natsis, Policy Coordinator presso la European Public Health Alliance, ha dichiarato non solo che le accuse di corruzione dimostrano che l’industria farmaceutica ancora una volta abusa del suo strapotere ma che, nonostante la Grecia potrebbe essere descritta come un paese in bancarotta, numerosi medicinali con prezzi esorbitanti, soprattutto quelli oncologici, sono ancora pienamente rimborsati dallo Stato: con profitti fiume per le multinazionali.


NOVARTIS UNDER SCRUTINY FOR ALLEGED PHARMA SCANDAL IN GREECE

EURACTIV

5 January 2017  

For Yannis Natsis, Policy Coordinator at the European Public Health Alliance, the bribery allegations do not come as a surprise and he doubts that this is a practice limited to Greece only.

Made with love by COCREATE

SUBSCRIBE TO OUR MAILING LIST

We publish our newsletter ten times a year to keep you informed about the latest news on public health in Europe. You can receive it directly in your mailbox.
First Name
Last Name
Email address
Secure and Spam free...